3.99
price up icon5.14%   0.195
after-market Handel nachbörslich: 3.96 -0.03 -0.75%
loading
Schlusskurs vom Vortag:
$3.795
Offen:
$3.83
24-Stunden-Volumen:
3.52M
Relative Volume:
1.75
Marktkapitalisierung:
$1.19B
Einnahmen:
$248.37M
Nettoeinkommen (Verlust:
$11.74M
KGV:
79.80
EPS:
0.05
Netto-Cashflow:
$18.24M
1W Leistung:
+6.40%
1M Leistung:
-3.16%
6M Leistung:
-40.80%
1J Leistung:
-26.52%
1-Tages-Spanne:
Value
$3.75
$3.99
1-Wochen-Bereich:
Value
$3.63
$3.99
52-Wochen-Spanne:
Value
$3.63
$7.63

Mannkind Corp Stock (MNKD) Company Profile

Name
Firmenname
Mannkind Corp
Name
Telefon
818-661-5000
Name
Adresse
1 CASPER STREET, DANBURY, CA
Name
Mitarbeiter
407
Name
Twitter
@MannKindCorp
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
MNKD's Discussions on Twitter

Vergleichen Sie MNKD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MNKD
Mannkind Corp
3.99 1.19B 248.37M 11.74M 18.24M 0.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-10 Eingeleitet Mizuho Outperform
2025-02-10 Eingeleitet Wedbush Outperform
2024-12-20 Eingeleitet Wells Fargo Overweight
2024-12-19 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-09-09 Fortgesetzt Leerink Partners Outperform
2024-06-13 Eingeleitet Rodman & Renshaw Buy
2023-10-10 Eingeleitet Wedbush Outperform
2021-05-14 Eingeleitet RBC Capital Mkts Sector Perform
2019-12-24 Eingeleitet Oppenheimer Outperform
2019-10-25 Eingeleitet Cantor Fitzgerald Overweight
2019-05-14 Eingeleitet BTIG Research Buy
2019-03-04 Eingeleitet SVB Leerink Outperform
2019-02-22 Eingeleitet SVB Leerink Outperform
2018-02-28 Herabstufung Maxim Group Hold → Sell
2017-11-01 Herabstufung Maxim Group Buy → Hold
2017-10-10 Eingeleitet H.C. Wainwright Buy
2017-10-06 Bestätigt Maxim Group Buy
2017-08-11 Eingeleitet Maxim Group Buy
2016-05-10 Bestätigt Piper Jaffray Underweight
2016-05-10 Bestätigt RBC Capital Mkts Underperform
2016-01-06 Bestätigt Piper Jaffray Underweight
2016-01-06 Bestätigt RBC Capital Mkts Underperform
2015-11-04 Herabstufung RBC Capital Mkts Outperform → Underperform
2015-09-09 Herabstufung Piper Jaffray Neutral → Underweight
2015-08-03 Bestätigt RBC Capital Mkts Outperform
2015-05-11 Herabstufung JP Morgan Neutral → Underweight
2015-05-11 Bestätigt MLV & Co Hold
2015-04-16 Bestätigt RBC Capital Mkts Outperform
Alle ansehen

Mannkind Corp Aktie (MNKD) Neueste Nachrichten

pulisher
Jun 17, 2025

MannKind stock hits 52-week low at $3.70 - Investing.com

Jun 17, 2025
pulisher
Jun 11, 2025

Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga

Jun 11, 2025
pulisher
Jun 10, 2025

Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech

Jun 10, 2025
pulisher
Jun 10, 2025

MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

MannKind to present inhaled insulin study at ADA event - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23 - Yahoo Finance

Jun 09, 2025
pulisher
Jun 05, 2025

MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

MannKind To Present At Jefferies Global Healthcare Conference; Webcast At 2:35 PM ET - Nasdaq

Jun 05, 2025
pulisher
May 28, 2025

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

May 28, 2025
pulisher
May 27, 2025

Type 1 Diabetes Didn't Stop This INDYCAR Driver: Conor Daly Inspires Detroit Youth Before Grand Prix - Stock Titan

May 27, 2025
pulisher
May 27, 2025

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha

May 27, 2025
pulisher
May 20, 2025

MannKind stock touches 52-week low at $4.34 amid market shifts - Investing.com Canada

May 20, 2025
pulisher
May 20, 2025

MannKind at RBC Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada

May 20, 2025
pulisher
May 20, 2025

MannKind at RBC Conference: Strategic Growth and Innovation - Investing.com

May 20, 2025
pulisher
May 20, 2025

MannKind To Present At RBC Capital Markets Conference; Webcast At 8:00 AM ET - Nasdaq

May 20, 2025
pulisher
May 16, 2025

Most adults with type 1 diabetes using inhaled insulin increase daily dose over 30 weeks - Healio

May 16, 2025
pulisher
May 15, 2025

MannKind corp director Steven Binder sells $375,875 in stock By Investing.com - Investing.com Nigeria

May 15, 2025
pulisher
May 15, 2025

MannKind EVP David Thomson sells shares worth $150,597 By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

MannKind EVP David Thomson sells shares worth $150,597 - Investing.com

May 15, 2025
pulisher
May 15, 2025

MannKind corp director Steven Binder sells $375,875 in stock - Investing.com

May 15, 2025
pulisher
May 15, 2025

MannKind CMO steps down, transition plan set - Investing.com

May 15, 2025
pulisher
May 13, 2025

MannKind to Present at Upcoming Investor Conferences - The Globe and Mail

May 13, 2025
pulisher
May 11, 2025

MannKind Corporation (NASDAQ:MNKD) Q1 2025 Earnings Call Transcript - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus

May 09, 2025
pulisher
May 08, 2025

10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey

May 08, 2025
pulisher
May 08, 2025

MannKind: Q1 Earnings Snapshot - MySA

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: MannKind Q1 2025 revenue beats, stock dips - Investing.com

May 08, 2025
pulisher
May 08, 2025

MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Gr - GuruFocus

May 08, 2025
pulisher
May 08, 2025

MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Growth | MNKD Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

MannKind Corp Q1 2025 Earnings: EPS Meets Estimates at $0.04, Revenue Surpasses Expectations at $78 Million - GuruFocus

May 08, 2025
pulisher
May 08, 2025

MannKind Corporation Reports First Quarter 2025 Financial Results - TradingView

May 08, 2025
pulisher
May 08, 2025

MANNKIND CORP SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Ex - GuruFocus

May 07, 2025
pulisher
May 07, 2025

MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance

May 07, 2025
pulisher
May 01, 2025

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 - The Globe and Mail

May 01, 2025
pulisher
Apr 29, 2025

The Potential Rise in the Price of Mannkind Corp (MNKD) following insiders activity - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

Solidion Technology Inc’s latest rating changes from various analysts - knoxdaily.com

Apr 29, 2025
pulisher
Apr 23, 2025

MNKD (Mannkind Corp) may reap gains as insiders became active recently - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Mannkind Corp (MNKD) is looking forward to a strong quarter - Sete News

Apr 23, 2025

Finanzdaten der Mannkind Corp-Aktie (MNKD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Kapitalisierung:     |  Volumen (24h):